Subject(s)
Coccidioides/isolation & purification , Coccidioidomycosis/microbiology , Lung Transplantation/adverse effects , Tissue Donors , Travel , Antibodies, Fungal/blood , Antifungal Agents/therapeutic use , Arizona , Coccidioides/immunology , Coccidioidomycosis/diagnosis , Coccidioidomycosis/drug therapy , Coccidioidomycosis/transmission , France , Humans , Idiopathic Pulmonary Fibrosis/surgery , Immunosuppressive Agents/therapeutic use , Itraconazole/therapeutic use , Male , Middle Aged , Treatment OutcomeABSTRACT
Candida tropicalis is a diploid ascomycetes yeast responsible for 4%-24% of candidemia. Resistance to flucytosine is rarely described for this species but was observed for 45 (35%) of 130 C. tropicalis isolates recovered from blood cultures in the Paris area in a 4-year survey. The aims of this study were to test the hypothesis that the flucytosine-resistant isolates could represent a subgroup and to determine the relationship between epidemiologic and genomic data. Epidemiologic data and gene sequences were analyzed, and molecular typing was performed. Our results suggest that a clone of flucytosine-resistant isolates, associated with malignancies and a lower mortality than that for other C. tropicalis isolates, is widespread in the Paris area. We propose the analysis of 2 polymorphic microsatellite markers coupled with URA3 sequencing to track the clone.
